Royalty Pharma plc Class A (RPRX)
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RPRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $39.36B
- P/E (TTM)
- 44.74
- Forward P/E
- 11.62
- EPS (TTM)
- $1.53
- Dividend yield
- 1.35% ($0.925)
- Ex-dividend date
- Nov 13, 2026
- 52-week range
- 37.31 – 70.37
- Day range
- 67.95 – 68.83
- Volume / Avg
- 3.53M / 3.21M
- Beta
- —
- Shares outstanding
- 445.27M
52-week range
RPRX stock today
On Nov 20, RPRX ended the session at $68.45, adding $0.73 (1.08%), versus the S&P 500's 3.70% decline. At this level, RPRX sits near the top of its 52-week range of $37.31 to $70.37: 2.7% below the high, set on Nov 12, 2026 and 83.5% above the low. RPRX is up 77.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 75.9%.
At 44.7x trailing earnings, Royalty Pharma trades in line with the peer-group median of 43.2x. Its forward P/E of 11.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Royalty Pharma pays an annual dividend of $0.925 per share, a 1.35% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Royalty Pharma
Company profileRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Pablo Legorreta
- Headquarters
- New York, NY
- Employees
- 100
- IPO year
- 2020
- Website
- royaltypharma.com
Financial highlights
Full financialsIn fiscal 2025, Royalty Pharma generated $2.38 billion in revenue, up 5.1% from fiscal 2024. Net income was $770.9 million (-10.2% year over year), for a net margin of 32.4% versus a median of 37.9% in the prior 5 years. Operating margin was 65.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Growth | +5.06% | -3.86% | +5.24% | -2.28% | +7.87% |
| Net income | $770.95M | $858.98M | $1.13B | $42.83M | $619.73M |
| EPS (diluted) | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$75.25+9.93%
- Strong buy 2
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.32 vs $1.18
- Surprise
- -72.88%
Dividends
Dividend history- Annual dividend
- $0.925
- Dividend yield
- 1.35%
- Last payment
- $0.235
- Ex-dividend date
- Nov 13, 2026
- Pay date
- Dec 10, 2026
RPRX news
All RPRX news- RPRX vs. ILMN: Which Stock Should Value Investors Buy Now?NasdaqRPRX, ILMN
- Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha
- AUSF, RPRX, RSG, LIN: ETF Outflow AlertNasdaqAUSF, RPRX, RSG, LIN
- Royalty Pharma to present at the UBS Global Biopharma ConferenceGlobeNewswire
- Royalty Pharma: Stronger Royalty Growth Supports Further UpsideSeeking Alpha
- RPRX Ex-Dividend Reminder - 11/13/26NasdaqRPRX, PBE, MOG.B
- Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer DrugNasdaqRVMD, RPRX, MOG.A
- Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?Nasdaq
Royalty Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ONCBeOne Medicines Ltd. ADR | 390.94 | -2.19% | $44.66B | vs RPRX |
| ZTSZoetis Inc. Class A | 79.11 | -2.08% | $32.14B | vs RPRX |
| TEVATeva Pharmaceutical Industries Limited | 39.23 | +1.79% | $45.77B | vs RPRX |
| GMABGenmab A/S ADS | 50.60 | -1.46% | $31.20B | vs RPRX |
| INSMInsmed Incorporated | 141.33 | -2.17% | $31.01B | vs RPRX |
| ROIVRoivant Sciences Ltd. | 38.66 | -0.78% | $28.01B | vs RPRX |
| UTHRUnited Therapeutics Corporation | 554.73 | -0.78% | $23.63B | vs RPRX |
| VTRSViatris Inc. | 19.63 | -1.26% | $22.50B | vs RPRX |
Indexes, lists and sector
Royalty Pharma stock FAQ
What is Royalty Pharma's stock price today?
RPRX last traded at $68.45 as of Nov 20, 4:00 PM EST, up 1.08% on the day. Prices are delayed at least 15 minutes.
Does Royalty Pharma pay a dividend?
Yes. Royalty Pharma pays $0.925 per share annually, a 1.35% yield. The most recent dividend of $0.235 had an ex-dividend date of Nov 13, 2026.
What is RPRX's P/E ratio?
RPRX trades at a trailing P/E ratio of 44.74 and a forward P/E of 11.62, compared with a median of 43.2 for its closest peers.
Who is Royalty Pharma's CEO?
Mr. Pablo Legorreta is the chief executive officer of Royalty Pharma plc Class A, which has about 100 employees.
What is the RPRX 52-week high?
The 52-week high for RPRX is $70.37 and the 52-week low is $37.31. The stock is currently 2.7% below its high.